Annals of dermatology最新文献

{"title":"Interferon Gamma and Secretory Immunoglobulin A Levels Decrease in Persistent Anal Condyloma Acuminatum Infection.","authors":"Yuanli Guo, Zi Zhang, Lipei Zhao, Xiaohui Ma, Tingting Mao, Xiaolei Cheng, Qiulin Gao, Manli Qi","doi":"10.5021/ad.24.145","DOIUrl":"10.5021/ad.24.145","url":null,"abstract":"<p><strong>Background: </strong>Condyloma acuminatum (CA) is a common sexually transmitted disease caused by human papillomavirus (HPV). In recent years, research on anal CA has primarily focused on treatment rather than underlying mechanisms. The mechanism of HPV persistence and recurrence in CA require further exploration. It needs multiple researches in mechanisms to focalize treatment targets.</p><p><strong>Objective: </strong>To investigate the relationship between intestinal mucosal immunity and the relapse of anal CA and persistent infection.</p><p><strong>Methods: </strong>Levels of interferon gamma (IFN-γ) and secretory immunoglobulin A (sIgA) were measured using enzyme-linked immunosorbnent assay in anal mucosal cells obtained from patients treated at Tianjin Union Medical Center from September 2022 to December 2024. All the participants signed Informed Consent and the whole plan was approved by Institutional Review Board in Tianjin Union Medical Center (No. B155).</p><p><strong>Results: </strong>The levels of IFN-γ and sIgA significantly decreased after infection, and persistent infection exhibited even lower levels. These two factors increased following treatment, reaching peak concentrations at 4 weeks before decreasing again.</p><p><strong>Conclusion: </strong>These findings demonstrate a significant association between persistent anal CA infection and dysregulation of intestinal mucosal immunity.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 3","pages":"140-145"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Clinical Practice on Skin Rejuvenation Among Korean Board-Certified Dermatologists: Survey-Based Results.","authors":"Sejin Oh, Yeong Ho Kim, Bo Ri Kim, Hyun-Min Seo, Soon-Hyo Kwon, Hoon Choi, Haewoong Lee, Jung-Im Na, Chun Pill Choi, Joo Yeon Ko, Hwa Jung Ryu, Suk Bae Seo, Jong Hee Lee, Hei Sung Kim, Chang-Hun Huh","doi":"10.5021/ad.24.167","DOIUrl":"10.5021/ad.24.167","url":null,"abstract":"<p><strong>Background: </strong>Skin rejuvenation has become an increasingly popular noninvasive approach to address age-related changes such as sagging, wrinkles, and skin laxity. Energy-based devices (EBDs) and injectables are widely used, but their application requires careful customization based on individual patient characteristics to optimize outcomes and minimize potential adverse effects.</p><p><strong>Objective: </strong>This study aimed to explore clinical practice patterns among board-certified dermatologists in South Korea, focusing on their strategies for tailoring skin rejuvenation treatments to individual patients, including the integration of EBDs, injectables, and senotherapeutics.</p><p><strong>Methods: </strong>A structured survey comprising 10 questions was administered to 13 experienced dermatologists specializing in skin rejuvenation. The survey covered treatment strategies for patients with varying facial fat volumes, pain management approaches, and the use of EBDs, injectables and senotherapeutics.</p><p><strong>Results: </strong>High-intensity focused ultrasound (HIFU) and radiofrequency (RF) were the most employed EBDs, often combined with injectables for enhanced outcomes. For patients with higher facial fat, HIFU and deoxycholic acid injections were preferred for contouring and tightening. For those with lower facial fat, biostimulatory agents such as poly-D, L-lactic acid and microneedle RF were favored to restore volume and elasticity. Pain management strategies included topical anesthetics and stepwise protocols. Although less commonly used, senotherapeutics were occasionally prescribed for specific conditions, such as melasma and extensive photoaging.</p><p><strong>Conclusion: </strong>Dermatologists in South Korea employ a variety of patient-specific strategies for skin rejuvenation, combining various EBDs, injectables, and senotherapeutics. These findings highlight the importance of personalized treatment protocols and the need for further research to optimize treatment efficacy and safety.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 3","pages":"123-130"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrical Stimulation Using a Low-Frequency and Low-Intensity Alternating Current Modulates Type I Procollagen Production and MMP-1 Expression in Dermal Fibroblasts.","authors":"Bo Mi Kang, Jung Min Ahn, Jieun Kim, Kyungho Paik, Bo Ri Kim, Dong Hun Lee, Sang Woong Youn, Keun-Yong Eom, Chong Won Choi","doi":"10.5021/ad.25.001","DOIUrl":"10.5021/ad.25.001","url":null,"abstract":"<p><strong>Background: </strong>Despite various therapeutic modalities for keloids have been introduced; however, their therapeutic effects are limited. Therefore, the development of a new approach for inhibiting collagen production by scar fibroblasts is needed.</p><p><strong>Objective: </strong>To investigate the effect of electrical stimulation using a low-frequency and low-intensity alternating current on collagen and MMP-1 levels in human dermal fibroblasts.</p><p><strong>Methods: </strong>Low-frequency (20 kHz) and low-intensity (1 V/cm) electrical stimulations were applied to primary dermal fibroblasts. The production of type I procollagen and expression of matrix metalloproteinase-1 were evaluated. Transcriptomic analyses were conducted to explore the possible modes of action of electrical stimulation.</p><p><strong>Results: </strong>Electrical stimulation effectively suppressed type I procollagen production and increased MMP-1 expression. In addition, transcriptomic analyses revealed that electrical stimulation altered the gene expression associated with membrane permeability and the structure of cellular membranes. Validation using real-time polymerase chain reaction revealed that electrical stimulation significantly altered the expression of mechanosensitive ion channels (<i>PIEZO2</i>) and membrane-bound protein organizing caveolae (<i>CAVIN2</i>).</p><p><strong>Conclusion: </strong>Electrical stimulation using low-frequency and low-intensity alternating currents effectively modulates extracellular matrix homeostasis by altering the cellular membrane structure and function. Our findings suggest a promising therapeutic approach for the management of keloids and hypertrophic scars.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 3","pages":"152-161"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Ustekinumab and Guselkumab in Improving Itch in Severe Psoriasis Patients.","authors":"Ji Hoon Ryoo, Nam Gyoung Ha, Han Jin Jung, Dae-Lyong Ha, Jun Young Kim, Weon Ju Lee, Yong Hyun Jang","doi":"10.5021/ad.25.012","DOIUrl":"10.5021/ad.25.012","url":null,"abstract":"<p><strong>Background: </strong>Biologics effectively improve psoriatic skin lesions, but their impact on itch relief remains unclear.</p><p><strong>Objective: </strong>To evaluate itch improvement in severe psoriasis patients treated with ustekinumab or guselkumab.</p><p><strong>Methods: </strong>This retrospective study analyzed patients with severe psoriasis who completed initial efficacy evaluations after treatment with either biologic. Itch severity was assessed using numerical rating scale (NRS), visual analog scale, and verbal rating scale. NRS improvement was evaluated after three injections.</p><p><strong>Results: </strong>Among 108 patients (74 on ustekinumab, 34 on guselkumab), 77 (71.3%) had moderate-to-severe itch (NRS ≥4) at baseline. Of these, 63 (81.8%) achieved an NRS improvement of ≥4 points. Ustekinumab showed greater itch relief compared to guselkumab in NRS (<i>p</i>=0.033). On the other hand, guselkumab showed more reduction for psoriatic skin lesions than ustekinumab in the Psoriasis Area and Severity Index (<i>p</i>=0.040). In the moderate-to-severe itch group, patients with large plaques experienced significantly greater improvement in NRS than those with small plaques (<i>p</i>=0.012).</p><p><strong>Conclusion: </strong>While guselkumab is generally preferred for psoriatic skin lesions, ustekinumab may provide superior itch relief.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 3","pages":"146-151"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contact Sensitization to Methylchloroisothiazolinone/Methylisothiazolinone is Associated With Poor Treatment Outcome: A Retrospective Study.","authors":"Jae Joon Jeon, You Hyun Kim, Seung-Won Jung, Solam Lee, Eung Ho Choi","doi":"10.5021/ad.24.150","DOIUrl":"10.5021/ad.24.150","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 3","pages":"169-171"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cutaneous CD30+ Lymphoproliferative Disorders in South Korea: A Nationwide, Multi-Center, Retrospective, Clinical, and Prognostic Study.","authors":"Woo Jin Lee, Sook Jung Yun, Joon Min Jung, Joo Yeon Ko, Kwang Ho Kim, Dong Hyun Kim, Myung Hwa Kim, You Chan Kim, Jung Eun Kim, Chan-Ho Na, Je-Ho Mun, Jong Bin Park, Ji-Hye Park, Hai-Jin Park, Dong Hoon Shin, Jeonghyun Shin, Sang Ho Oh, Seok-Kweon Yun, Dongyoun Lee, Seok-Jong Lee, Seung Ho Lee, Young Bok Lee, Soyun Cho, Sooyeon Choi, Jae Eun Choi, Mi Woo Lee","doi":"10.5021/ad.24.120","DOIUrl":"10.5021/ad.24.120","url":null,"abstract":"<p><strong>Background: </strong>Primary cutaneous CD30+ lymphoproliferative disorders (pcCD30-LPDs) are a diseases with various clinical and prognostic characteristics.</p><p><strong>Objective: </strong>Increasing our knowledge of the clinical characteristics of pcCD30-LPDs and identifying potential prognostic variables in an Asian population.</p><p><strong>Methods: </strong>Clinicopathological features and survival data of pcCD30-LPD cases obtained from 22 hospitals in South Korea were examined.</p><p><strong>Results: </strong>A total of 413 cases of pcCD30-LPDs (lymphomatoid papulosis [LYP], n=237; primary cutaneous anaplastic large cell lymphoma [C-ALCL], n=176) were included. Ninety percent of LYP patients and roughly 50% of C-ALCL patients presented with multiple skin lesions. Both LYP and C-ALCL affected the lower limbs most frequently. Multiplicity and advanced T stage of LYP lesions were associated with a chronic course longer than 6 months. Clinical morphology with patch lesions and elevated serum lactate dehydrogenase were significantly associated with LPDs during follow-up in LYP patients. Extracutaneous involvement of C-ALCL occurred in 13.2% of patients. Lesions larger than 5 cm and increased serum lactate dehydrogenase were associated with a poor prognosis in C-ALCL. The survival of patients with C-ALCL was unaffected by the anatomical locations of skin lesions or other pathological factors.</p><p><strong>Conclusion: </strong>The multiplicity or size of skin lesions was associated with a chronic course of LYP and survival among patients with C-ALCL.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"75-85"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice.","authors":"Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.5021/ad.24.127","DOIUrl":"10.5021/ad.24.127","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic eczematous disorder characterized by intense itchiness. Systemic therapies for AD include Janus kinase (JAK) inhibitors and various biological agents. The effects of transitioning from the JAK1 inhibitor, upadacitinib, to the anti-interleukin 13 antibody, tralokinumab, remain unclear.</p><p><strong>Objective: </strong>This study evaluated the transition from 15 mg of upadacitinib to tralokinumab in patients with moderate-to-severe AD.</p><p><strong>Methods: </strong>This analysis included 20 patients who switched from 15 mg of upadacitinib to tralokinumab due to an inadequate response or adverse events (AEs). We assessed the total and regional eczema area and severity index (EASI), which included assessments of the head and neck, trunk, and upper and lower limbs, along with erythema, edema/papulation, excoriation, lichenification, and the peak pruritus numerical-rating scale (PP-NRS), initially (start of 15 mg of upadacitinib), at the transition point (week 0), and during follow-up at weeks 4 and 12.</p><p><strong>Results: </strong>The EASI, EASI of the four anatomical regions, and EASI of the four clinical manifestations significantly declined from baseline at weeks 4 and 12, with no substantial reductions from week 0. The PP-NRS score notably decreased from baseline at week 4. Achieving EASI of 50 and 75 improved post-switching.</p><p><strong>Conclusion: </strong>Transitioning to tralokinumab substantially alleviated rash in patients with AD who experienced suboptimal responses or AEs to 15 mg of upadacitinib.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"86-95"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative Tumor Density of Soft-Tissue Sarcoma in Korean Population: An Institutional Review.","authors":"Bo Bin Cha, Jung Yup Kim, Won-Serk Kim, Ga-Young Lee, Young-Jun Choi","doi":"10.5021/ad.23.122","DOIUrl":"10.5021/ad.23.122","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive studies on the tumor burden of soft-tissue sarcoma (STS) by anatomical site are lacking in Asian populations.</p><p><strong>Objective: </strong>To investigate the anatomical distribution of STS via relative tumor density (RTD) in a Korean cohort.</p><p><strong>Methods: </strong>The RTDs of patients with STS at a single-institution from 2007-2022 were retrospectively analyzed. To describe the STS locations, the body was divided into 4 anatomical sites, and the RTD of each was calculated to the compare topographic tumor burden.</p><p><strong>Results: </strong>Fifty-nine cases in 58 individuals, 35 male (60.3%) and 23 female (39.7%), with a mean age of 56.5±20.4 were analyzed. Overall, the most frequent STS site was the lower extremity (LE, n=22, 37.3%), and the highest RTD was in the head and neck (H&N, 2.44; 95% confidence interval, 1.39-3.77). Dermatofibrosarcoma protuberans (DFSP), Kaposi's sarcoma (KS), and angiosarcoma (AS) accounted for 76.3% of all the cases. DFSP, KS, and AS showed significantly higher RTD on the trunk (2.55, <i>p</i>=0.025), LE (3.88, <i>p</i><0.001), and H&N (7.42, <i>p</i><0.001), respectively, than elsewhere.</p><p><strong>Conclusion: </strong>Each STS displays topographic variability and produces different topographic tumor burdens by body site in an Asian population.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"96-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy, Safety and Longevity of Biologic Treatments in Pediatric and Adult Psoriasis Patients: A Comparative Multi-Center, Real-Life Study.","authors":"Özlem Akın Çakıcı, Zeynep Topkarcı, Begüm Yurtsever Güneş, Nahide Onsun, Dilek Seçkin, Tülin Ergun","doi":"10.5021/ad.24.057","DOIUrl":"10.5021/ad.24.057","url":null,"abstract":"<p><strong>Background: </strong>Evidence on the effectiveness, long-term safety and longevity of biologic therapies in pediatric psoriasis patients is sparse.</p><p><strong>Objective: </strong>This study aims to compares the efficacy, safety and drug survival (DS) rates of etanercept (ETA), adalimumab (ADA), infliximab (INF), ustekinumab (UST), secukinumab (SEC) and ixekizumab (IXE) in pediatric and adult psoriasis patients.</p><p><strong>Methods: </strong>293 biologic treatment cycles of 198 patients (62 pediatric and 136 adult) from three academic psoriasis referral centres were analysed.</p><p><strong>Results: </strong>The following were the Psoriasis Area and Severity Index 90 response scores of pediatric and adult psoriasis patients, respectively: ETA, 42.3% vs. 34.6%; ADA, 53.8% vs. 59.8%; INF, 33.3% vs. 33.3%; UST, 76.5% vs. 56.8%; SEC, 60% vs. 60%; and IXE, 50% vs. 87.5%. The differences of responses between the two groups were statistically insignificant (<i>p</i>>0.05). ETA had the longest mean DS time in the pediatric group but it was related to a significantly shorter DS in pediatric patients than in adults (pediatrics: 30.58 [18.64-42.52] months vs. adults: 72.34 [54.70-89.99] months; <i>p</i>=0.025). ADA had the longest mean DS time in the adult group with 101.28 [84.88-117.68] months. All treatments had favorable safety profiles. No specific severe adverse effects necessitating treatment discontinuation were observed in pediatric patients.</p><p><strong>Conclusion: </strong>Although responses to ETA and UST were numerically better among children, the difference was insignificant. The DS rates in each group were comparable, and no specific safety signals, limiting the long-term use of these agents, were detected in the pediatric group.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"114-121"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional Use of Hyaluronic Acid-Based Dissolving Microneedle Patches to Treat Psoriatic Plaques: A Randomized Controlled Trial.","authors":"Hyun Jeong Ju, Ji Yoon Kim, Do Hyeon Jeong, Moon-Su Lee, Gyong Moon Kim, Jung Min Bae, Ji Hae Lee","doi":"10.5021/ad.24.024","DOIUrl":"10.5021/ad.24.024","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in systemic targeted therapies, topical agents remain the primary treatment for localized psoriasis. However, their therapeutic effects are often delayed and unsatisfactory. The dissolving microneedle (DMN) patch, a novel transdermal drug delivery system, enhances the absorption of topical agents through micro-channels.</p><p><strong>Objective: </strong>To evaluate the efficacy of DMN patches in enhancing drug delivery and improving clinical outcomes in psoriatic plaques.</p><p><strong>Methods: </strong>A prospective, randomized, split-body study was conducted to verify the efficacy of additional use of DMN patches after topical agent application in psoriasis treatment. Patients with mild psoriasis were enrolled and 6 paired lesions per patient were randomized into 3 groups: ointment-only, ointment-with-no needle patch, and ointment-with-DMN patch. Lesions were treated with a topical agent (betamethasone and calcipotriol) once daily for 2 weeks. Modified psoriasis area and severity index (mPASI) scores were measured weekly. <i>In vitro</i> and <i>ex vivo</i> experiments were performed to confirm micro-channel formation, microneedle dissolution, and drug penetration enhancement.</p><p><strong>Results: </strong>A total of 132 paired lesions from 22 patients were analyzed. The ointment-with-DMN patch group showed significantly improved mPASI scores (80.4%±20.5%; 5.42→1.06) compared to the ointment-with-no needle patch (64.6%±33.0%; 4.94→1.68) (<i>p</i><0.05) and ointment-only groups (55.5%±31.4%; 5.00→2.15) (<i>p</i><0.001). <i>In vitro</i> studies demonstrated 2.1-fold enhanced drug delivery with DMN patches, while <i>ex vivo</i> histological analysis confirmed micro-channel formation. No adverse events, including infection or psoriasis exacerbation, were observed.</p><p><strong>Conclusion: </strong>The DMN patch is an effective adjunctive tool that enhances transdermal drug delivery and improves therapeutic outcomes in psoriatic plaques, particularly those refractory to topical agents.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02955576.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}